Oncimmune Regulatory News (ONC)

5 November 2018

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Annual Report and Accounts and AGM Notification

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today gives notice that copies of the Annual Report and Accounts for the year ended 31 May 2018 and the Notice of Annual General Meeting ("AGM") have been sent to shareholders. These documents are available to view on the "Investors" section of the Company's website at http://oncimmune.com/. Oncimmune announced results for the year ended 31 May 2018 on 31 October 2018.

Further copies of the Annual Report will be available from the Company Secretary, Oncimmune, Clinical Sciences Building, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB.

Oncimmune also announces that its Annual General Meeting will be held 30 November 2018. The meeting will be held at Peachey & Co LLP, 95 Aldwych, London, WC2B 4JF, commencing at 9.30 am.

-Ends-

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, John Goold

+44 (0)20 3829 5000

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

+44 (0)20 7332 2500

Berenberg (Joint Broker)

Toby Flaux, Alix Mecklenburg-Solodkoff

+44 (0)20 3207 7800

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

Oncimmune@consilium-comms.com

+44 (0)20 3709 5708

About Oncimmune

Beating cancer, one test at a time

Oncimmune is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body's natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT®-Lung and EarlyCDT®-Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT®-Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered in Nottingham, UK with a CLIA lab in Kansas, US and offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

For more information, visit http://oncimmune.com/